[Clinical study of the selective anxiolytic agent afobazol].
A standard clinical trial including pharmaco-EEG investigation of the new selective anxiolytic afobazole was performed on a group of 30 patients with anxiety and anxious-asthenic disorders and premorbid individual asthenic profile traits. Afobazole exhibits the anxiolytic action with an activating component in the absence of sedative and myorelaxant effects. The clinical trial results confirmed good prospects of using the experimentally validated pharmacogenetic concept of anxioselectivity as a methodological approach to the design of new drugs possessing selective anxiolytic properties.
Neznamov
G G
GG
Laboratory of Clinical Psychopharmacology, Russian Academy of Medical Sciences, Baltiiskaya ul. 8, Moscow, 125315 Russia.
Siuniakov
S A
SA
Chumakov
D V
DV
Bochkarev
V K
VK
Seredenin
S B
SB
D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D004569:Electroencephalography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D009440:Neurasthenia / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D013315:Stress, Psychological / Q000523:psychology
C410924:2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole; D014151:Anti-Anxiety Agents; D001562:Benzimidazoles; D009025:Morpholines